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ABSTRACT
Xenogeneic-free media are required for translating advanced therapeutic medicinal products to
the clinics. In addition, process efﬁciency is crucial for ensuring cost efﬁciency, especially when
considering large-scale production of mesenchymal stem cells (MSCs). Human platelet lysate
(HPL) has been increasingly adopted as an alternative for fetal bovine serum (FBS) for MSCs.
However, its therapeutic and regenerative potential in vivo is largely unexplored. Herein, we
compare the effects of FBS and HPL supplementation for a scalable, microcarrier-based dynamic
expansion of human periosteum-derived cells (hPDCs) while assessing their bone forming capac-
ity by subcutaneous implantation in small animal model. We observed that HPL resulted in faster
cell proliferation with a total fold increase of 5.2  0.61 in comparison to 2.7  02.22-fold in
FBS. Cell viability and trilineage differentiation capability were maintained by HPL, although a
suppression of adipogenic differentiation potential was observed. Differences in mRNA expres-
sion proﬁles were also observed between the two on several markers. When implanted, we
observed a signiﬁcant difference between the bone forming capacity of cells expanded in FBS
and HPL, with HPL supplementation resulting in almost three times more mineralized tissue
within calcium phosphate scaffolds. FBS-expanded cells resulted in a ﬁbrous tissue structure,
whereas HPL resulted in mineralized tissue formation, which can be classiﬁed as newly formed
bone, veriﬁed by μCT and histological analysis. We also observed the presence of blood vessels
in our explants. In conclusion, we suggest that replacing FBS with HPL in bioreactor-based expan-
sion of hPDCs is an optimal solution that increases expansion efﬁciency along with promoting
bone forming capacity of these cells. STEM CELLS TRANSLATIONAL MEDICINE 2019;00:1–12
SIGNIFICANCE STATEMENT
Current research in the ﬁeld of Stem Cell Bioprocessing has highlighted the need for xeno-free
media and that will enhance process efﬁciency while facilitating clinical translation. This work
provides important data and support toward the use of platelet lysate as a viable alternative to
fetal bovine serum in a scalable suspension cell culture set-up. Although HPL is increasingly con-
sidered for several progenitor cell types as a suitable medium for culture, there are no studies
evaluating these cells in an in vivo setting. In this study, strikingly hPDCs were seen to be able
to form signiﬁcantly higher amount of bone when implanted together with CaP carriers in small
animal models. This capacity was linked to activation of WNT and BMP pathways associated
with the osteogenic capacity of several progenitor cells.
INTRODUCTION
The ﬁelds of cell-based therapy, tissue engineer-
ing, and regenerative medicine aim to address
unmet clinical challenges by using stem/pro-
genitor cells as main therapeutic substances.
Multipotent adult progenitors (encountered in
multiple sources in the human body) are espe-
cially attractive due to their relatively easy
availability and better safety proﬁle in compari-
son to pluripotent stem cells. This is highlighted




theus, Division of Skeletal Tis-
sue Engineering, KU Leuven,




Received October 4, 2018;




This is an open access article
under the terms of the Creative
Commons Attribution-
NonCommercial-NoDerivs
License, which permits use and
distribution in any medium,
provided the original work is
properly cited, the use is non-
commercial and no modiﬁca-
tions or adaptations are made.
STEM CELLS TRANSLATIONAL MEDICINE 2019;00:1–12 www.StemCellsTM.com © 2019 The Authors.
STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
MANUFACTURING FOR REGENERATIVE MEDICINE
850 registered clinical trials using MSCs (MSCs at clinicaltrials.
gov), in comparison to the approximate 500 trials registered in
June 2015 [1]. From these, 26 studies are focused on bone frac-
ture healing and 11 for nonunions. It is estimated that for pre-
clinical investigations using large animal models and clinical
trials, the required number of progenitor cells could go up to
millions per treatment. For example, it has been reported that
between 15 and 45 million MSCs may be required for cartilage
regeneration in joint surface defects and the number can go up
to 600 million for a tibia defect of 4 cm [1–3]. Hence, the devel-
opment of scalable and automated bioprocesses that could con-
tribute to cost-efﬁcient production of cell-based therapeutics,
compliant with Good Manufacturing Practices, is necessary.
The efﬁciency of bioreactor-based processes is dependent
on various extrinsic culture parameters. A key process parame-
ter for such manufacturing processes is the culture medium
and its composition. Traditionally, culture media used for most
mammalian cells included fetal bovine serum (FBS) as a sup-
plement. However, FBS possesses certain drawbacks, such as
high lot-to-lot variation, potential for pathogen transfer, xeno-
geneic contaminations, and even limited supply. To address
these issues, a shift toward alternate supplements and chemi-
cally deﬁned media (CDM) has been advocated and intensively
investigated. Human platelet lysate (HPL) has been suggested
as an alternative option for FBS in recent years. It contains vari-
ous growth factors like Transforming growth factor-β, Platelet
derived growth factor, Insulin-like growth factor-1, bFGF,
Epidermal growth factor, and Vascular endothelial growth
factor along with adhesive proteins like ﬁbrinogen and ﬁbronectin
[4, 5]. Similar to FBS, HPL also can have lot-to-lot variation due to
its human origin. However, the large batch production method of
commercially available HPL reduces the effect of such variation.
The use of large number of donors (20–120 donors) also aids in
decreasing lot-to-lot variations [6]. Extensive work has been car-
ried out in two-dimensional (2D) static culture to investigate the
use of HPL as an alternative to FBS for culture of MSCs from differ-
ent sources including bone marrow (BM), umbilical cord blood
(UCB), adipose tissue, and corneal stroma [7–12]. It was consis-
tently reported that HPL supplementation resulted in enhanced
cell proliferation in comparison to FBS. For example, the popula-
tion doubling time for BM MSCs (between P1 and P2) in 10% FBS
was reported to be approximately 20 days in comparison to 6 days
for 10% HPL [7]. Schallmoser et al. and Capelli et al. also reported
the feasibility of clinical scale expansion of MSCs from BM aspi-
rate without any prior manipulation using HPL [8, 13]. It has also
been reported that use of HPL enhances osteogenic and
chondrogenic differentiation capabilities of MSCs in vitro [14–17].
With success in static cultures, HPL has also been used for
expansion of MSCs within bioreactor set-ups. The earliest
reported study for HPL-based MSC expansion in a bioreactor
system was carried out by Petry et al. in 2015 wherein UCB
MSCs were expanded using 10% HPL supplemented medium,
on microcarriers in spinner ﬂasks [18]. Heathman et al. also
[19] demonstrated in 2016 that the use of HPL in microcarrier-
based spinner ﬂask culture of BM MSCs resulted in a smaller
lag phase and increased yield in comparison to FBS. They fur-
ther showed that the use of HPL increased interdonor consis-
tency contributing to robust bioprocess outcomes and hence
aiding the use of MSCs in clinical settings. In the same year, it
was also reported that HPL supplemented medium could be
used to isolate UCB MSCs and subsequently expand them
using spinner ﬂasks [20]. Since the publication of these
pioneering works, multiple studies have been carried out to
expand MSCs from various sources using HPL supplementation in
different bioreactor systems like stirred reactors of different vol-
umes (100 ml to 50 l) [21–23] and hollow ﬁber systems [24–26].
Human periosteum-derived stem cells (hPDCs) have shown
to play a key role in fracture healing via the formation of a
transient ﬁbrocartilaginous callus that is subsequently mineral-
ized and replaced de novo by bone via endochondral ossiﬁca-
tion [27–29]. It has also been reported that in fracture healing,
growth factors such as bone morphogenetic proteins (BMP)
and β-catenin/wingless-related factors (WNT) are released from
cells at the fracture site to recruit and trigger skeletal progenitor
cells in the periosteum to aid the healing process. Hence, activa-
tion of BMP and WNT signaling is an important indicator of cell
bone forming capacity [30]. There is an increasing research activ-
ity on their use as a cell’s source for the production of skeletal
Advanced Therapy Medicinal Products (ATMPs). From a biopsy
of 1 g periosteum, it can roughly be estimated that 150,000 skel-
etal progenitor cells (plastic adhesive) can be isolated for further
in vitro expansion. This low initial cell number renders efﬁcient
expansion processes crucial for the successful implementation of
hPDC-based ATMPs. Under serum containing conditions, hPDCs
have shown in vitro expansion potential for up to 30 population
doublings exhibiting a ﬁbroblast-like morphology and a popula-
tion doubling time of 55 hours [2]. PDCs after ex vivo expansion
have shown to have characteristics similar to MSCs derived from
other sources [30–33]. Additionally, they have shown to possess
superior bone forming properties to BM-derived and other MSC
types when implanted subcutaneously on calcium phosphate
(CaP) carriers [34, 35]. In previous studies, we have expanded
hPDCs in various types of bioreactor including spinner ﬂasks [2,
36–38]. Furthermore, when cultured in perfusion bioreactors in
osteoinductive medium, hPDCs have shown to be able to differ-
entiate into the osteogenic lineage producing mineralized extra-
cellular matrix [39, 40], whereas in a spinner ﬂask system, they
were capable of undergoing chondrogenic differentiation [36].
Various studies have highlighted the positive effect of HPL
on osteogenic differentiation of MSCs in vitro in 2D as well as
in three-dimensional scaffold-based culture [16, 17, 41]. How-
ever, only one study to date has shown in vivo bone forming
capacity of statically cultured BM-MSCs in HPL supplemented
medium [42]. To the best of authors’ knowledge, there is no
reported study on the in vivo bone forming capacity of adult
MSC populations expanded in bioreactors in HPL supplemented
medium. In this work, the use of HPL for microcarrier-based
expansion of hPDCs in spinner ﬂasks was investigated in compari-
son to FBS supplementation. Differences in gene expression sig-
nature regarding MSC-markers (cluster of differentiation [CD]73,
CD90, CD105), chondrogenic differentiation (SOX9, aggrecan
[ACAN], collagen II [COL II], COLX), and osteogenic differentiation
(RUNX2, collagen I [COL I], Osteocalcin [OCN], alkaline phospha-
tase [ALP], BMP2, WNT5) were investigated [30, 43]. Subse-
quently, the in vivo bone forming capacity of the expanded cell
populations was evaluated using an ectopic model.
MATERIALS AND METHODS
hPDCs Static Culture
Human PDCs were obtained from periosteal biopsies with
informed consent from the patient and approval of the Ethics
© 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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Committee for Human Medical Research (KU Leuven). Pooled
hPDCs from four individual donors were expanded and
maintained in high glucose containing Dulbecco’s modiﬁed Eagle’s
medium (DMEM, Invitrogen, Belgium) supplemented with 10%
FBS (Hyclone, U.K.), 1% sodium pyruvate (Invitrogen), and 1%
antibiotic–antimycotic (Invitrogen). Cells were incubated in a
humidiﬁed incubator at 37C with 5% CO2. They were monitored
regularly and on reaching a conﬂuence of 90%, were detached
with Tryple E (Invitrogen) and used for further experiments.
Spinner Flask Culture
One hundred milliliters spinner ﬂasks with paddle-based impeller
from Bellco Biotechnology (Bellco Glass, Inc., VWR International,
Belgium) were used with a ﬁnal volume of 80 ml. Coating of the
ﬂasks with SigmaCote (Sigma–Aldrich, St. Louis, MO) was carried
out prior to usage. Cultispher S microcarriers (GE Healthcare,
Belgium) at a concentration of 1 mg/ml were weighed, hydrated
using phosphate-buffered saline (PBS), and sterilized by autoclav-
ing. Twenty-four hours prior to the seeding of spinner ﬂasks, T-
ﬂask expanded cells were put through a serum starvation pro-
cess. Brieﬂy, regular culture medium was removed from the
ﬂasks followed by PBS washes to remove all media traces. Com-
plete medium containing 0.1% FBS was added to the ﬂasks and
incubated overnight. The low serum-based medium was
removed, cells were washed with PBS, followed by seeding in
spinner ﬂasks with appropriate complete medium (either with
10% FBS or with 10% HPL [Stemulate, Cook Regentec, U.K.]).
The microcarriers were also equilibrated prior to use by incubat-
ing them in culture medium overnight. A seeding density of
2.5 × 104 cells per milliliter along with attachment and expan-
sion protocols in spinner ﬂasks were selected based on previous
publication [36]. hPDCs were expanded for 10 days in the spin-
ner ﬂask with 50% medium replacement every third day. Ten
percentage HPL-based medium was selected based on prelimi-
nary static culture comparison (data not shown) and was com-
pared with established 10% FBS supplementation. At speciﬁc
time points throughout the experiment, cells and media were
stored for analyses.
Cell Count and DNA Quantiﬁcation
Cell viability and growth were estimated by DNA quantiﬁcation
and Trypan blue-based cell count. Cultispher S microcarriers were
dissolved using collagenase type IV (Life Technologies, Belgium) in
order to harvest the cells. For DNA quantiﬁcation, cells were col-
lected in lysis buffer (Qiagen, The Netherlands) and supplemented
with β-mercaptoethanol followed by 30 seconds vortexing. Qubit
dsDNA HS assay kit (Molecular Probes, Thermo Scientiﬁc, Belgium)
was used for DNA measurement following manufacturer’s proto-
col using Qubit Fluorometer (Invitrogen).
Medium Analysis
Metabolites were measured using Cedex Bio Analyzer (Roche
Custom Biotech, Belgium). The media supernatant were col-
lected and analyzed. Ammonia concentration was normalized
with respect to its production in cell-free set-up due to gluta-
mine degradation. Speciﬁc metabolite consumption/production
rate were calculated using Equation 1 [36].
qmet =
Cmet tð Þ −Cmet t−1ð Þ
X × t
ð1Þ
where qmet = cell-speciﬁc metabolite consumption/production
rate; Cmet(t) = concentration of metabolite measured at the
end of time point t; Cmet(t − 1) = concentration of metabolite at
the start; and X = cell number at time t (day).
Live–Dead Assay
Live/Dead kit from Molecular Probes, Thermo Scientiﬁc was
used to qualitatively analyze live and dead cells. Brieﬂy, cell
samples were taken from the spinner ﬂask and washed twice
with PBS. 0.5 μl of Calcein-AM (4 mM stock) and 2 μl of
Ethidium Homodimer (2 mM stock) was added to 1 ml of PBS.
One hundred microliters of the solution was added to the
samples and incubated at 37C for 30 minutes, followed by
washing in PBS twice. They were then observed under ﬂuores-
cence microscope (Discovery V8, Zeiss, Oberkochen, Germany).
DAPI, Phalloidin Staining
Cells on microcarriers were collected from the spinner ﬂask for
actin ﬁlament and nucleus staining. The cells were ﬁxed using 4%
paraformaldehyde (PFA) followed by incubation in 0.1 M glycine
solution for 15 minutes. Cells were incubated for 20 minutes at
room temperature in staining solution containing 2.5 μl of DAPI
(1 mg/ml stock solution), 4 μl of phalloidin (200 U/ml stock con-
centration Alexa Fluor 488, phalloidin, Life Technologies), and
20 μl of Triton-X per ml of PBS followed by imaging using confo-
cal microscope (Zeiss, Oberkochen, Germany).
RNA Extraction, cDNA Synthesis, and qPCR Analysis
Total RNA was extracted using RNeasy mini kit (Qiagen) and
was quantiﬁed using NanoDrop ND-1000 spectrophotometer
(Thermo Scientiﬁc, Belgium). cDNA was synthesized using
RevertAid H Minus ﬁrst strand cDNA synthesis kit (Thermo Sci-
entiﬁc, Belgium) for 500 ng of RNA. cDNA was stored at −20C
at a ﬁnal concentration of 3.33 ng/μl. qPCR was carried out
using SyBR Green Mastermix (ThermoFisher Scientiﬁc, Wal-
tham, MA). The PCR cycle used was −45C for 2 minutes, 95C
for 30 seconds, 40 cycles of 95C for 3 seconds, and 60C for
20 seconds. Each sample was tested in duplicate and compared
with β-actin expression that allowed normalization of results.
Relative differences in expression were calculated using the
2−ΔΔCT method.
MSC Phenotyping
Harvested cells were assessed based on a combined positivity
for typical MSC CD markers and lack of expression for hemato-
poietic markers [36]. The used antibody panel was CD90-FITC,
CD73-APC, CD105-PE, CD14, CD20, CD34, and CD45-PerCP
(Miltenyi Biotec, Gladbach, Germany). Dead cells were excluded
based on a viability dye. Flow cytometric analysis was carried
out using BD FACS Canto. Automatic single-color compensation
was performed by the acquisition software (BD FACSDiva, Frank-
lin lakes, NJ) using compensation beads (UltraComp eBeads
Affymetrix eBioscience, St Louis, MO). The gating was based on
Fluorescence Minus One controls.
Trilineage in vitro Differentiation Potential Analysis
In order to assess the multipotency maintenance capability of
the cells, their trilineage differentiation, that is, chondrogenic,
osteogenic, and adipogenic differentiation capability in vitro
was tested [36, 44].
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Chondrogenic differentiation of the hPDCs was assessed in
a micromass assay. Brieﬂy, 2 × 105 cells were resuspended in
10 μl of regular culture medium and seeded as micromasses.
After 2 hours of incubation, 0.5 ml of standard culture medium
was added. After overnight incubation, the medium was rep-
laced by chondrogenic medium consisting of DMEM/F12 (Life
Technologies), 2% FBS, 1% antibiotic–antimycotic, 1% ITS Premix
(Corning, New York, NY), 100 nM dexamethasone (Sigma, Bel-
gium), 10 M Y27632 (Axon Medchem, Gronignen, NL),
50 g/ml ascorbic acid, 40 g/ml proline, and 10 ng/ml recom-
binant human transforming growth factor β-1 (Preprotech,
U.K.). After 7 days of chondrogenic induction, micromasses
were ﬁxed in ice-cold methanol and stained at room tempera-
ture for 1 hour with a 0.1% Alcian blue solution in 0.1 M HCl at
pH 1.2. Alcian blue was extracted using 6 M guanidine hydro-
chloride and absorbance was measured at 620 nm.
Osteogenic differentiation was assessed by seeding the
cells at a density of 4,500 cells per cm2 in 0.5 ml culture
medium. After 48 hours, the medium was replaced by stan-
dard culture medium supplemented with 100 mM dexametha-
sone, 50 g/ml ascorbic acid, and 10 mM β-glycerolphosphate.
After 21 days, cells were ﬁxed prior to analysis in ice-cold
methanol for 1 hour and afterward stained with a 2% alizarin
red S solution in Baxter water. Ten percentage cetylpyridinium
chloride was used for stain extraction and measured at 540 nm.
Adipogenic differentiation was investigated by seeding
the cultured hPDCs at a density of 1 × 104 cells per cm2 in 0.5 ml
standard culture medium. After 24 hours, the medium was rep-
laced by adipogenic medium consisting of α-MEM (Life Technolo-
gies) supplemented with 10% FBS, 1% antibiotic–antimycotic, 1 M
dexamethasone, 10 g/ml human insulin (Sigma), 100 M indometh-
acin (Sigma), and 25 M 3-isobutyl-1-methylxanthine (Sigma). After
approximately 14 days (fat globules seen), cells were ﬁxed in 10%
formaldehyde for 20 minutes, rinsed shortly with 60% isopropanol
and stained with Oil Red O. Staining from fat globules was
extracted using isopropanol and measured at 518 nm. Samples in
standard culture medium were used as negative control for all
cases.
Ectopic in vivo Implantation and Analysis
After 10 days of expansion, cells from spinner ﬂasks were
harvested using collagenase and ectopically implanted on the
back of nude mice for 8 weeks. 1 × 106 cells in a total volume
of 30 μl culture medium were seeded on clinical grade CaP
scaffolds (NuOss, ACE Surgical Supply Co., Inc., Hannover, Ger-
many). They were incubated overnight (37C, 5% CO2, 95%
RH) followed by ectopic implantation. Empty CaP scaffolds
were implanted as control. After 8 weeks, the explants were
retrieved, ﬁxed overnight in 4% PFA, and preserved in PBS
before scanning by x-ray computed tomography and histological
analysis. All animal experiments and procedures were approved
by the Animal Ethics Committee (KU Leuven).
The volume of newly formed mineralized tissue after 8 weeks
of in vivo implantation was determined by nano-Computed
Tomography (CT) performed on a Phoenix NanoTom M (GE Mea-
surement and Control) system. The applied scan settings were
60 kV x-ray voltage, 170 mA current, 500 milliseconds exposure
time, a frame averaging of 1 and image skip of 0 and with a
3 μm voxel size. Images were reconstructed with Phoenix
Datos x CT software (GE Measurement and Control). The
quantiﬁcation of the bone volume was based on a two-level
automatic Otsu segmentation algorithm. All image processing
was performed in CTAn (Bruker micro-CT, Kontich, BE).
At the end of CT analysis, the scaffolds were decalciﬁed using
EDTA for approximately 4 weeks followed by parafﬁn embed-
ding, sectioning (5 μm), and subsequent histological analysis.
Hematoxylin–eosin, Safranin O-Fast Green, and Masson’s
trichrome staining were carried out as per established protocols.
Statistical Analysis
All quantitative results were expressed as mean  SEM. One-
way analysis of variance followed by Dunnett’s multiple com-
parison test was performed using GraphPad Prism, version
6.00 for Windows (GraphPad Software, La Jolla, CA) in order
to ﬁnd statistical signiﬁcance of the data. Statistical signiﬁ-
cance analysis was carried out by comparing the experimental
set-ups with mainly day 0 (D0) control set-ups. Exceptions are
mentioned within the Materials and Methods and Results sec-
tions. Differences among data were considered to be statisti-
cally signiﬁcant if p < .05.
RESULTS
Viable Cell Count and DNA Quantiﬁcation
Preliminary studies showed that cell expansion with HPL in spin-
ner ﬂasks reached a plateau after day 10, suggesting that conﬂu-
ence may have been reached already at this time point. Hence,
we restricted our studies until day 10. Cell expansion in both
HPL-based and FBS-based media was regularly monitored via
trypan blue-based cell count and DNA quantiﬁcation. Cell
attachment and spreading on microcarriers were also visualized
based on actin and nucleus staining. As observed in Figure 1A,
1B, hPDCs were able to attach, spread uniformly, and proliferate
on Cultispher S in both FBS and HPL supplemented media. Due
to the opaque nature of Cultispher S, very little information can
be gathered regarding cell attachment and expansion from
phase-contrast microscopy. However, Figure 1C, 1D highlights
the heterogeneous nature of Cultispher S microcarriers.
Figure 1D also shows that by day 7, HPL-based medium results
in “bead bridging” and clumping in the system due to higher cell
density in comparison to FBS supplemented system. Both viable
cell count and DNA quantiﬁcation showed a steady increase in
both FBS and HPL supplemented media suggesting cell prolifera-
tion within the system (Fig. 2A, 2B). However, the cell number in
HPL was signiﬁcantly higher than the FBS-based system from day
4 onward (Fig. 2A). At the end of 10 days culture, HPL showed a
fold increase of 5.2  0.61 in comparison to that of FBS which
had a 2.7  02.22-fold expansion. A similar trend was also
observed for DNA quantiﬁcation from extracted cells.
Live–Dead Assay
Calcein–ethidium homodimer staining was carried out to quali-
tatively estimate cell viability and death. As shown in Figure 2C,
2D, staining for both systems shows that hPDCs were viable in
spinner ﬂasks with negligible cell death. Bead–bead adhesion
and clump formation were observed in both set-ups, but more
prominent in HPL supplemented medium.
Metabolite Analysis
Spent media collected at various time points were analyzed
for measuring and quantifying metabolites like glucose
© 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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consumption, lactate production, Lactate Dehydrogenase (LDH)
accumulation, and ammonia production. Glucose consumption
rate (Fig. 3A) was signiﬁcantly higher in HPL in comparison to
FBS set-up. The consumption showed a drop on day 10 for HPL
containing cultures, suggesting a decrease in metabolic activity,
which can be attributed to high-culture conﬂuence or differentia-
tion stage. Lactate production rate (Fig. 3B) and LDH production
rate (Fig. 3E) increased over time and were higher in HPL sup-
plemented medium in comparison to FBS, although a drop in
their production rate can be seen on day 10 in both the systems.
Lactate yield from glucose remained close to the theoretical value
of 2 for HPL-based culture afﬁrming that the system was metabol-
ically active and robust. However, interestingly, the FBS system
showed on days 4 and 7 a yield higher than the maximum the-
oretical value which decreased on day 10. Surprisingly, cumula-
tive ammonia production rate showed opposite trends in the
two systems. Within the FBS system, ammonia production
showed a slight increase between day 4 and day 7, followed by
a decrease on day 10. In contrast, HPL-based set-up showed a
sharp decrease in ammonia production between day 4 and day
7 followed by an increase on day 10. Overall, ammonia produc-
tion was higher in FBS than in comparison to HPL culture with
signiﬁcant differences on days 7 and 10.
MSC Phenotyping
Based on ﬂow cytometric analysis of spinner ﬂask expanded
cells, it was observed that for FBS supplementation, 89% of
the cells showed simultaneously positive expression of CD73,
CD90, and CD105 and negative expression for markers like
CD14, CD20, CD34, and CD45 while the number was 86% for
HPL supplemented set-up (Fig. 4A). The individual marker
expression at the protein level shows a slight drop in CD90
and CD73 expressing cell population (Fig. 4B).
In Vitro Trilineage Differentiation Capability
Trilineage differentiation capability of cells from spinner ﬂask
was measured and compared with control cells from T-ﬂask.
in vitro differentiation of cells toward chondrogenic, osteo-
genic, and adipogenic lineages were carried out (Fig. 5). Absor-
bance values of the different dyes after extraction were
measured and compared with control data. No difference was
observed for chondrogenic differentiation in both FBS and HPL
supplemented media. Osteogenic differentiation capability was
slightly upregulated in both HPL and FBS supplemented spin-
ner ﬂask culture in comparison to 2D control cultures. The
upregulation was more for HPL in comparison to FBS.
Figure 1. Visualization of human periosteum-derived cells attachment and expansion on Cultispher S for 10 days. (A): Nucleus-actin ﬁla-
ment staining in fetal bovine serum (FBS) supplemented media on day 10, (B) nucleus-actin ﬁlament staining in human platelet lysate
supplemented media on day 10, (C) phase-contrast image on day 7 for FBS supplemented media, (D) phase-contrast image on day 7 for
human platelet lysate supplemented media. Scale bars: (A, B) = 50 μm; (C, D) = 100 μm.
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Interestingly, adipogenic differentiation capability for HPL sup-
plemented system was signiﬁcantly downregulated in compari-
son to the FBS supplemented set-up.
mRNA Expression
qPCR-based analysis of mRNA expression was carried out for a
host of markers for an in-depth analysis of the culture process
at the end of 10-day culture period. Expression of the CD
markers at the mRNA level (Fig. 6A) showed that CD73 was sig-
niﬁcantly downregulated in FBS in comparison to HPL sup-
plemented culture. Both FBS-based and HPL-based systems
showed a decrease on CD90 and CD105 expression in compari-
son to the D0 control cells. Sox9 expression in HPL sup-
plemented set-up was signiﬁcantly higher in comparison to FBS
whereas ACAN and COL II followed the reverse pattern (Fig. 6B).
No signiﬁcant difference was observed for Collagen X (COL X),
RUNX2, and COL I. OCN was signiﬁcantly upregulated for FBS in
comparison to HPL whereas ALP had a signiﬁcantly higher
expression in HPL set-up in comparison to FBS (Fig. 6C). Both
BMP2 and WNT5A (Fig. 6D) were signiﬁcantly upregulated in
HPL in comparison to FBS. Adipogenic marker PPARγ expression
was lower in HPL-based system in comparison to FBS (Fig. 6E).
Micro-CT Analysis for in vivo Bone Formation
Spinner ﬂask expanded cells from both set-ups were ectopi-
cally implanted in nude mice using CaP scaffolds. After
8 weeks, the explants were analyzed for mineralized tissue
content to assess bone forming capacity of FBS and HPL in
spinner ﬂask-based expansion. CT analysis showed a clear
difference in bone forming capacity between HPL-based and
FBS-based system. As seen in Figure 7A, 7B, HPL showed
mature mineralized tissue within the scaffold whereas use of
FBS resulted in more ﬁbrous tissue formation. Quantiﬁcation
of the mineralized tissue showed that HPL expansion resulted
in a signiﬁcantly higher volume of mineralized tissue in com-
parison to FBS-based spinner ﬂask culture (Fig. 7C).
Histological Analysis
After μ-CT analysis, H&E, Safranin O-Fast Green, and Masson’s
trichrome staining were carried out for visualizing mineraliza-
tion within the CaP scaffolds. As seen in Figure 7D–7O, his-
tlogical staining supported μ-CT data. The FBS-based system
mainly showed ﬁbrous tissue structure within the scaffold with
only very small fragments of bone tissue being formed. In con-
trast, the HPL-based system showed a much higher fully miner-
alized tissue which can be classiﬁed as “de novo bone” within
the CaP scaffolds. Blood cell inﬁltration was also observed in
both cases (Fig. 7E, 7G).
DISCUSSION
Efﬁcient expansion of scarce autologous progenitor (MSC)
populations is critical for clinical implementation and commer-
cial viability of cell-based therapeutics [45]. Apart from their
high proliferation rate in vitro and their multipotent nature,
these cells also have lower regulatory and ethical complica-
tions than pluripotent cells, making their transition from bench
Figure 2. Quantiﬁcation of cell expansion in fetal bovine serum (FBS) and human platelet lysate (HPL)-based spinner ﬂask set-up. (A): Try-
pan blue-based viable cell count, (B) DNA quantiﬁcation of cell extracted from Cultispher S via collagenase treatment. (C): Live–dead quali-
tative analysis for FBS supplemented system on day 10, (D) live–dead qualitative analysis for HPL supplemented system on day 10. Merged
images show cells on Cultispher S to be alive. Cell-microcarrier aggregation is also visible, suggesting conﬂuence. Scale bar = 500 μm.
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to bedside relatively easier. hPDCs can be classiﬁed as MSCs
originating from the periosteum, proven by their phenotypic
characteristics [44]. However, methods for scaling up the
production of these cells are far from optimized to date.
Efforts have been made to optimize upstream bioprocessing
for MSCs using various bioreactor systems [46–48]. hPDCs
Figure 3. Metabolic analysis of spent media from spinner ﬂask culture over 10 days. (A): Glucose-speciﬁc consumption rate, (B) lactate-
speciﬁc production rate, (C) lactate yield from glucose, (D) ammonia-speciﬁc production rate, (E) LDH-speciﬁc production rate. ***,
p < .001. One-way analysis of variance followed by Dunnet’s multiple comparison test. Abbreviations: FBS, fetal bovine serum; HPL,
human platelet lysate; LDH, lactate dehydrogenase.
Figure 4. Mesenchymal stem cell (MSC) phenotypic markers expression. (A): Flow cytometric analysis for MSC marker combination
expressing cells, and (B) expression of individual MSC phenotyping marker population.
www.StemCellsTM.com © 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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have been expanded and differentiated using hollow ﬁber, par-
allel plate, and stirred type bioreactors [2, 36–38, 40]. Spinner
ﬂasks or stirred reactors are one of the most attractive biore-
actor set-ups due to their scalability and process ﬂexibility. In
this study, we explored FBS-based and HPL-based bioreactor
process for scalable hPDC expansion. Apart from in vitro char-
acterization, we evaluated the effects of HPL and FBS on the
bone forming capacity of hPDCs in a nude mice model. Even
though an increasing number of studies document the impact
of HPL on various MSC populations, there are very few reports
on the regenerative capacity of HPL-expanded cell populations
upon implantation and none for in vivo bone forming potential.
The current work showed that supplementing expansion
medium with HPL instead of FBS is beneﬁcial for a microcarrier-
based stirred process in terms of cell expansion, priming, and
postexpansion bone forming capacity in the ectopic nude mice
model. We observed and increased cell proliferation in HPL-
based culture in comparison to FBS. Our data is supported by
published proteomic analysis of HPL wherein analysis of extra-
cellular cues from HPL showed involvement of pathways related
to cell proliferation and wound repair [49]. Furthermore, glu-
cose consumption rate for HPL-based system was signiﬁcantly
higher on days 4 and 7 in comparison to FBS with a drop
toward the end of the expansion phase. For example, approxi-
mately 50% increase in glucose consumption rate was observed
for HPL in comparison to FBS on day 7. Lactate production rate
also showed a similar trend. Such a trend of lowered metabolic
activity has been previously reported for MSCs from BM in spin-
ner ﬂask culture, although the timeline was different due to dif-
ference in cell origin, culture protocol, seeding density, and so
on [50]. LDH production has been associated to cell death [51,
52] and also followed a pattern similar to lactate production.
This can be linked to both, a higher starting LDH concentration
in HPL in comparison to FBS, as well as faster cell growth and
higher cell number present in the HPL containing medium. In
contrast, ammonia production rate was different between the
two systems with FBS-based system showing higher production
rate in comparison to HPL. Ammonia has been primarily known
to be a by-product of glutamine degradation and consumption.
The differing trend of its production in the two systems sug-
gests that their glutamine catabolism is different. The lactate
yield from glucose values for HPL-based system was very near
to the theoretical value of 2 highlighting the metabolic robust-
ness of the HPL-based process, which is important for MSC pro-
liferation [53]. FBS supplementation, on the other hand, had a
lactate yield from glycose value higher than 2 in the initial cul-
ture period. This has been reported before for MSCs in bioreac-
tors and had been associated with the use of glutamine as an
alternative carbon source by the cells [46]. The high ammonia
production that we observed with FBS in the initial days of the
culture further supports this theory. This further highlights the
importance of metabolites and growth factor in the media along
with their role in cell metabolism and merits further studies.
Flow cytometric analysis at the end of the culture period
showed no discernible difference between the two systems in
terms of MSC phenotypic markers. A signiﬁcant difference was
observed in the mRNA expression of CD73 wherein the HPL
supplementation showed a higher expression in comparison to
FBS. CD73 as an ecto 50 nucloetidase plays an important role
in extracellular adenosine generation, although very little is
known about their exact role in MSCs. It has been reported
that CD73 is a regulator of osteo/chondrogenic differentiation
via the adenosine receptor pathway with its downregulation
supporting chondrogenesis in appropriate media [54, 55]. Others
have also reported the importance of CD73 in the immuno-
modulatory/immunosuppressive effects shown by MSCs [56, 57].
However, this difference in CD73 expression was not observed
at the protein level as evidenced by ﬂow cytometry, hence the
functional consequence is not known.
Considering HPL contains a wide variety of growth factors
and that shear stress is a known factor in affecting cells’ pheno-
typic state, we measured the expression of various differentia-
tion related markers at the mRNA level, which highlighted
interesting differences between FBS and HPL supplementation.
Figure 5. Analysis of trilineage differentiation capability of human periosteum-derived cells after 10 days of spinner ﬂask culture, (A)
qualitative analysis of Alcian blue, alizarin red, and Oil Red O staining for analyzing chondrogenic, osteogenic, and adipogenic differentia-
tion potential, respectively. (B): Quantitative measurement of extracted dye from chondrogenic, osteogenic, and adipogenic differentia-
tion. Fold change was calculated in comparison to differentiation of cells from T ﬂask expansion in HPL and FBS as appropriate. Scale bar
for chondrogenic and osteogenic = 500 μm. Scale bar for adipogenic = 100 μm. *, p < .05; one-way analysis of variance followed by
Dunnet’s multiple comparison test. Abbreviations: FBS, fetal bovine serum; HPL, human platelet lysate.
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Figure 6. Quantitative analysis of mRNA expressions via qPCR for FBS and HPL supplemented spinner ﬂasks at the end of 10 day culture
period. (A): CD73, CD90, and CD105 expressions, (B) Sox9, ACAN, COL II, and COL X expressions. (C): RUNX2, COL I, OCN, and ALP expres-
sions. (D): BMP2, WNT5A, (E) PPARγ. *, p < .05; ***, p < .001; one-way analysis of variance followed by Dunnet’s multiple comparison
test. Abbreviations: ACAN, aggrecan; ALP, alkaline phosphatase; BMP2, bone morphogenetic protein-2; COL I, collagen I; FBS, fetal bovine
serum; HPL, human platelet lysate; OCN, osteocalcin; WNT5A, wingless-related factor-5A.
Figure 7. (A): Representative image of μ-CT analysis for estimating mineralized tissue within CaP scaffolds for HPL-based system, (B) rep-
resentative image of μ-CT analysis for estimating mineralized tissue within CaP scaffolds for fetal bovine serum (FBS)-based system, (C)
Quantiﬁcation of mineralized tissue volume in CaP scaffolds for HPL and FBS-based spinner ﬂask culture after 8 weeks of ectopic implan-
tation. Abbreviations: S, CaP scaffold particle; M, mineralized tissue. *, p < .05; one-way analysis of variance. (D–O): Histological analysis
of 8 week nude mice explants of CaP scaffolds with human periosteum-derived cells grown in spinner ﬂask using FBS and human platelet
lysate (HPL)-based media. (D, E): H&E staining for HPL system explants, (F, G) H&E staining for FBS system explants, (H, I) Saf O-fast green
staining for HPL system explants, (J, K) Saf O-fast green staining for FBS system explants, (L, M) Masson’s trichrome staining for HPL sys-
tem explants, (N, O) Masson’s trichrome staining for FBS system explants. Abbreviations: S, scaffold grain; B, de novo bone/mineralized
tissue; F, ﬁbrous tissue; B.C., blood cells. Scale bar = 200 μm.
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The mRNA expression level of early osteochondrogenic tran-
scription factor, SOX9 was signiﬁcantly higher in HPL containing
medium in comparison to FBS. Sox9 is considered to be a mas-
ter regulator for chondrogenesis and is expressed in the early
stages of differentiation [58] and also regulates expression of
both ACAN and COL II at a later stage [59–62]. COL II and ACAN
had signiﬁcantly higher expression in FBS containing medium
along with OCN. For example, COL II expression showed approx-
imately 130% increase in HPL-based culture in comparison to
FBS. RUNX2, which is also a marker for osteochondro progeni-
tors had a higher expression in HPL-based system. The expres-
sion level of the hypertrophic (late chondrogenic) marker COL X
remained low in both cases but was slightly higher in FBS in
comparison to HPL. Taken together, these data may suggest
that HPL maintain hPDCs at an earlier stage of differentiation in
terms of chondrogenesis in comparison to FBS which might be
pushing the hPDCs toward a more committed differentiation
state. It could be also postulated that an osteochondral progeni-
tor population could be preferentially expanded in HPL. In addi-
tion, the early osteogenic marker ALP was signiﬁcantly higher in
HPL than FBS [63]. Similar observations have been reported pre-
viously by Castrén et al. for 2D HPL and FBS culture [64]. They
suggested that the differences in the temporal proﬁle can be
attributed to the presence of different growth factors in FBS
and HPL.
In vitro trilineage differentiation capability of the hPDCs
after spinner ﬂask-based expansion was carried out as well. No
discernible difference was seen between HPL and FBS supple-
mentation on chondrogenic differentiation whereas osteogenic
differentiation was nonsigniﬁcantly elevated in HPL. However,
we noticed a signiﬁcant drop in adipogenic differentiation capa-
bility of cells when expanded in HPL in comparison to FBS. This
was highlighted further by a decreased mRNA expression level
for PPARγ in HPL containing system in comparison to FBS. This
observation could also support the theory of preferential expan-
sion of osteochondral progenitor subpopulations in HPL. Similar
observations, that is, higher osteogenic and lower adipogenic
differentiation potential of BM MSC in HPL-based medium has
been reported previously [41, 65].
In order to assess the functionality of the expanded hPDCs,
we harvested cells and implanted them ectopically in nude mice
using CaP scaffolds using a robust in vivo assay developed previ-
ously [66]. μ-CT analysis showed that cells expanded in HPL
formed mature mineralized tissue within the CaP scaffolds
whereas FBS-expanded cells exhibited a more ﬁbrous morphol-
ogy. HPL supplementation also showed a signiﬁcantly higher per-
centage of mineralization in comparison to FBS. This was clearly
supported by H&E as well as Safranin O-Fast Green staining
whereas Masson’s trichrome showed higher quantity of newly
formed bone in the HPL-expanded hPDCs in contrast to the col-
lagenous and ﬁbrous tissue generated by the FBS-expanded cells.
The increase in osteogenic potential of hPDCs in HPL, as seen in
the in vitro trilineage differentiation assay, appeared to be a pre-
lude to the in vivo observations. In an effort to elucidate the rea-
son behind this difference in ectopic bone formation capacity,
we evaluated mRNA expression levels of BMP2 and WNT5A, two
key players in MSC osteogenic differentiation pathways [43].
qPCR analysis showed that both BMP2 and WNT5A expression
were signiﬁcantly higher in HPL-based system in comparison to
FBS at the end of spinner ﬂask expansion. It has been previously
reported that in vivo bone formation by hPDCs on CaP scaffolds
is promoted by upregulation of BMP and WNT pathways and
that early expression of BMP and WNT promoted osteogenesis
[30]. This report further supports our hypothesis that the
observed high expression of BMP2 and WNT5A in HPL sup-
plemented system primes the hPDCs toward improved bone for-
mation in vivo. WNT5A has also been reported to be a repressor
of PPARγ expression [67] which is in sync with our observations
of high WNT5A expression, lower PPARγ expression, and lower
adipogenic potential of hPDCs expanded in HPL. Both BMP2 and
WNT5A speciﬁcally have also been reported to promote MSC
osteogenesis [68–71]. The high expression level of these two
markers in our HPL supplemented culture may partially explain
the marked difference in in vivo bone formation as observed in
the nude mice model. In addition, a recent publication has
reported a global phenotypic analysis of surface markers for
MSCs cultured in FBS and HPL. Importantly, it was reported that
differential expression on multiple markers in HPL-expanded cells
was speciﬁcally related to pathways involved in proliferation,
osteogenic differentiation, and inﬂammatory responses [72]. This
further supports our observation of increased proliferation and
higher in vivo bone formatting capacity of hPDCs expanded in
spinner ﬂasks using HPL supplemented medium.
CONCLUSION
Our current work and published data from various other
groups highlight the beneﬁts of HPL in MSC expansion and dif-
ferentiation. However, due to its origin, it has to be kept in
mind that HPL may also have lot-to-lot variation and requires
basic checks and preliminary studies on changing its procure-
ment source and method. Performing similar studies with dif-
ferent batches of HPL may provide additional robustness to
the data. Additionally, evaluating HPL expansion on hPDCs,
freshly isolated from periost biopsies and then serially expanded
until clinically relevant cell populations are reached, remains to
be studied. In addition to the use of HPL, CDM can substitute
the use of serum in cell culture along with minimizing problems
arising due to batch-to-batch variation. Different groups have
studied the feasibility of using serum free CDM for the expan-
sion of MSCs in 2D as well as in microcarrier-based expansion in
spinner ﬂasks. It was demonstrated that in 2D culture, growth
of MSCs in CDM was similar to serum-based medium, whereas
donor-dependent variation was decreased on using CDM [73,
74]. However, it was reported that cell attachment and growth
on microcarriers was slower on using CDM in comparison to
FBS-based set-up. This was attributed to the lack of various
growth factors which are integral within a serum-based medium
[75]. We demonstrated that replacing FBS with HPL as culture
medium for spinner ﬂask-based expansion of hPDCs on collagen
microcarriers had multiple positive effects. These included a
dramatic increase in cell proliferation and at the same time a
signiﬁcant improvement in bone forming capacity of expanded
hPDCs, which is of utmost importance to autologous manufac-
ture. In addition, the faster proliferation of MSCs in HPL, is
expected to decrease the overall culture period signiﬁcantly
which in turn is expected to make the use of HPL more cost-
effective in the long run. Evidence for functionality of expanded
progenitor populations is often omitted from studies investigat-
ing HPL as an alternative expansion medium; thus, we believe
that this study addresses an important question in the ﬁeld of
© 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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cell therapy bioprocessing. These observations render the use
of HPL for bone tissue engineering a suitable strategy resulting
in bioprocesses of higher efﬁciency with the potential of
improved clinical outcomes.
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